Beta
Prasugrel
medication Under reviewAn antiplatelet medication used to reduce the risk of thrombotic cardiovascular events in patients with acute coronary syndrome.
Research summary
Human clinical research on prasugrel is extensive but is almost entirely conducted in patients with acute coronary syndromes or established cardiovascular disease rather than in healthy volunteers. These studies consistently show that prasugrel produces faster, more potent, and less variable inhibition of platelet aggregation compared with older agents such as clopidogrel, translating into lower rates of major adverse cardiovascular events like myocardial infarction and stent thrombosis in high-risk populations. At the same time, the research consensus is that prasugrel increases the risk of major bleeding, particularly in older adults, those with low body weight, and individuals with a prior stroke or transient ischemic attack. Because of this risk profile and its status as a prescription drug, prasugrel is not used for primary prevention in healthy people and has no evidence base as a general health or longevity supplement. Its benefits are specific to secondary prevention of thrombotic events in selected cardiac patients.
Reported Benefits
No reports yet
Be the first to report this effect and help the community.
Add Prasugrel to your stack to report effects
Phase II evaluation of prasugrel’s antiplatelet effects compared with clopidogrel
Winters KJ, Jakubowski JA, Naganuma H, et al.
Prasugrel plus aspirin beyond 12 months is associated with improved outcomes after Taxus Liberté paclitaxel-eluting coronary stent placement: results from the DAPT Study
Mauri L, Kereiakes DJ, Yeh RW, et al.
No reports yet
Be the first to report this effect and help the community.
Add Prasugrel to your stack to report effects
Phase II evaluation of prasugrel’s antiplatelet effects compared with clopidogrel
Winters KJ, Jakubowski JA, Naganuma H, et al.
No reports yet
Be the first to report this effect and help the community.
Add Prasugrel to your stack to report effects
Prasugrel plus aspirin beyond 12 months is associated with improved outcomes after Taxus Liberté paclitaxel-eluting coronary stent placement: results from the DAPT Study
Mauri L, Kereiakes DJ, Yeh RW, et al.
No side effects tracked yet
No side effects have been reported by studies or users for this habit yet.
Related health conditions
Research showing how this habit affects specific health conditions. Always consult healthcare professionals.
May Help With
Coronary artery disease or other cardiac conditions
Prasugrel plus aspirin beyond 12 months is associated with improved outcomes after Taxus Liberté paclitaxel-eluting coronary stent placement: results from the DAPT Study
Mauri L, Kereiakes DJ, Yeh RW, et al.
Phase II evaluation of prasugrel’s antiplatelet effects compared with clopidogrel
Winters KJ, Jakubowski JA, Naganuma H, et al.
Hypertension — elevated blood pressure requiring management
Phase II evaluation of prasugrel’s antiplatelet effects compared with clopidogrel
Winters KJ, Jakubowski JA, Naganuma H, et al.
Elevated LDL cholesterol or total cholesterol levels
Phase II evaluation of prasugrel’s antiplatelet effects compared with clopidogrel
Winters KJ, Jakubowski JA, Naganuma H, et al.
Research (2 studies)
Prasugrel plus aspirin beyond 12 months is associated with improved outcomes after Taxus Liberté paclitaxel-eluting coronary stent placement: results from the DAPT Study
Mauri L, Kereiakes DJ, Yeh RW, et al.
Phase II evaluation of prasugrel’s antiplatelet effects compared with clopidogrel
Winters KJ, Jakubowski JA, Naganuma H, et al.
Community updates
No updates yet for this supplement.
Be the first to share your experience!